DSpace Repository

Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

Show simple item record

dc.contributor.author Gürbüz, M.
dc.contributor.author Akkuş, E.
dc.contributor.author Sakin, A.
dc.contributor.author Urvay, S.
dc.contributor.author Demiray, Atike Gökçen
dc.contributor.author Şahin, S.
dc.contributor.author Şakalar, T.
dc.contributor.author Erol, C.
dc.contributor.author Şendur, M.A.N.
dc.contributor.author Şahin, A.B.
dc.contributor.author Çubukçu, E.
dc.contributor.author Güven, D.C.
dc.contributor.author Kılıçkap, S.
dc.contributor.author Ergün, Y.
dc.contributor.author Uncu, D.
dc.contributor.author Turhal, N.S.
dc.contributor.author Üskent, N.
dc.contributor.author Yeşil Çınkır, H.
dc.contributor.author Demir, A.
dc.contributor.author Acar, R.
dc.contributor.author Karadurmuş, N.
dc.contributor.author Türker, S.
dc.contributor.author Altınbaş, M.
dc.contributor.author Karaoğlan, M.
dc.contributor.author Çay Şenler, F.
dc.date.accessioned 2021-02-02T09:27:05Z
dc.date.available 2021-02-02T09:27:05Z
dc.date.issued 2020
dc.identifier.issn 03008916 (ISSN)
dc.identifier.uri http://hdl.handle.net/11499/37564
dc.description.abstract Purpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma. Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity. Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8–6.4) and 5.3 months (95% CI 2.6–8), respectively (p = 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3–13.9) and 15.2 months (95% CI 12.7–17.7), respectively (p = 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia. Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients. © Fondazione IRCCS Istituto Nazionale dei Tumori 2020.
dc.language.iso English
dc.publisher SAGE Publications Ltd
dc.relation.isversionof 10.1177/0300891620969823
dc.rights info:eu-repo/semantics/closedAccess
dc.subject Chemotherapy
dc.subject gastric cancer
dc.subject HER2
dc.subject trastuzumab
dc.title Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
dc.type Article
dc.relation.journal Tumori
dc.contributor.authorID 0000-0003-4397-5468
dc.relation.publicationCategory Uluslararası Hakemli Dergi
dc.identifier.index Scopus
dc.identifier.index PubMed


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record